Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539473 | 1.00 | KDM4E (0.36) | KDM4EGLAGAAPIK3CAMTOR | |
| SCHEMBL24316436 | 0.80 | KDM4E (0.37) | KDM4EGLAGAAPIK3CAMTOR | |
| SCHEMBL24316808 | 0.76 | POLB (0.41) | KDM4EGLAGAAPIK3CAMTOR | |
| SCHEMBL24316428 | 0.76 | ALKBH1 (0.39) | KDM4EGRM5ALDH1A1HPGDMCHR1 | |
| SCHEMBL17383465 | 0.75 | RXFP1 (0.43) | KDM4EGLAGAAPIK3CAMTOR | |
| SCHEMBL24316432 | 0.75 | ACACB (0.37) | PIK3CAMTORGRM5ALDH1A1HPGD | |
| SCHEMBL24316556 | 0.74 | KDM4E (0.41) | KDM4EGLAGAAPIK3CAMTOR | |
| SCHEMBL24316659 | 0.74 | ALKBH1 (0.40) | KDM4EGRM5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL24316797 | 0.74 | KDM4E (0.38) | KDM4EGLAGAAPIK3CAMTOR | |
| SCHEMBL22297931 | 0.74 | KDM4E (0.33) | KDM4EGLAGAAPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-03-21 | — | — | US | disclosed |
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | CYP2D6, CYP3A7, CYP2F1 | KDM4E 4085/4885GLA 1120/4885GAA 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.